Evommune (NYSE:EVMN) CEO Luis Pena Sells 16,787 Shares

Evommune, Inc. (NYSE:EVMN) CEO Luis Pena sold 16,787 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $22.74, for a total value of $381,736.38. Following the transaction, the chief executive officer owned 637,896 shares in the company, valued at approximately $14,505,755.04. This trade represents a 2.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Evommune Stock Performance

Evommune stock opened at $19.78 on Thursday. The business’s fifty day moving average is $23.98. Evommune, Inc. has a one year low of $13.89 and a one year high of $33.20. The company has a market cap of $712.62 million and a price-to-earnings ratio of -2.08.

Evommune (NYSE:EVMN) last released its earnings results on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.19. On average, equities analysts expect that Evommune, Inc. will post -2.83 earnings per share for the current year.

Analysts Set New Price Targets

EVMN has been the topic of several recent analyst reports. Wall Street Zen raised shares of Evommune from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Evommune in a research note on Tuesday, May 26th. Morgan Stanley lifted their price target on Evommune from $54.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Oppenheimer began coverage on Evommune in a research note on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 price target on the stock. Finally, Evercore reiterated an “outperform” rating and issued a $55.00 price target on shares of Evommune in a research note on Tuesday, February 10th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $49.25.

Institutional Investors Weigh In On Evommune

Hedge funds and other institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. bought a new stake in shares of Evommune during the 4th quarter valued at approximately $34,000. Strs Ohio bought a new stake in Evommune during the 1st quarter worth $41,000. The Manufacturers Life Insurance Company bought a new stake in Evommune during the 4th quarter worth $179,000. XTX Topco Ltd bought a new stake in Evommune during the 4th quarter worth $321,000. Finally, Oxford Asset Management LLP bought a new stake in Evommune during the 4th quarter worth $335,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.